Build a Better Process
Stock Risk Measures for Esperion Therapeutics Inc
A quantitative factor review as of September 30, 2021.
- Company Info - Description, identity and sector data.
- Share Data - Stock earnings and key dates.
- Market Risk - Beta, size, liquidity and momentum measures.
- Financial Risk - Earnings and dividends.
Updated: October 05, 2021
See how we arrive at an overall risk score of
for ESPR below.
An ad-free and cookie-free website.
ESPR Risk Report
Our quantitative data points are meant to provide a high-level understanding of
factors in equity risk models for Esperion Therapeutics Inc. Portfolio managers use these
models to forecast risk, optimize portfolios and review performance.
We show how ESPR stock compares to 2,000+ US-based stocks, and to
peers in the Manufacturing sector and Pharmaceutical Preparation Manufacturing industry.
Please do not consider this data as investment advice. Data is downloaded from
sources we deem reliable, but errors may occur.
Through scientific and clinical excellence, and a deep understanding of cholesterol biology, the experienced Lipid Management Team at Esperion is committed to developing new LDL-C lowering medicines that will make a substantial impact on reducing global cardiovascular disease, the leading cause of death around the world.
- Symbol: ESPR
- FactorPad FPID: f22ctm
- SEC CIK: 0001434868
- Share Class FIGI: BBG004KB3SZ1
- Location: Ann Arbor, Michigan US
- Web: www.esperion.com
Sector and Industry
- Sector: Manufacturing
- Industry: Pharmaceutical Preparation Manufacturing
- SIC Code: 2834
- Shares Outstanding: 28,277,493
Earnings and Dividends
- Trailing 12-month earnings: -12.14
- Next earnings date: 2021-11-02
- Dividend yield in last 12 months: 0%
- Ex-dividend date:
Market Risk Measures
Many of the following risk metrics are standardized and transformed into
quantitative factors in institutional-level risk models.
Rankings below represent percentiles from 1 to 100, with 1 being the lowest
rating of risk.
Stocks with higher beta exhibit higher sensitivity to the ups and downs
in the market. (↑↑)
Beta: 0.46 |
Stocks with higher market capitalization often have lower risk. (↑↓)
Market Capitalization: $331,694,993 |
Higher average daily dollar volume over the past 30 days implies lower
liquidity risk. (↑↓)
Daily Dollar Volume: $11,976,591 |
Higher price momentum stocks, aka recent winners, equate to lower risk for many
Stock Price Change (1-Year): -65.68% |
Financial Risk Measures
Style risk factors often include measures of profitability and payout levels.
Companies with higher earnings generally provide lower risk. (↑↓)
Earnings Yield (E/P): -100.74% |
Companies with higher dividend yields, if sustaintable, are perceived to
have lower risk. (↑↓)
Dividend Yield (D/P): 0% |
ESPR stock risk
ESPERION THERAPEUTICS INC stock beta
ESPR risk report
ESPR risk analysis
ESPERION THERAPEUTICS INC credit risk
ESPR liquidity risk
ESPR systematic risk
ESPR specific risk
ESPERION THERAPEUTICS INC volatility
ESPR financial ratio
A newly-updated free resource. Connect and refer a friend today.